Shedding kinetics of soluble tumor necrosis factor (TNF) receptors after systemic TNF leaking during isolated limb perfusion. Relevance to the pathophysiology of septic shock

Journal of Clinical Investigation

Volumn 101, Issue 3, 1998, Pages 650-659

  Aderka, Dan ^a,d   Sorkine, Patrick ^a   Abu Abid, Subchi ^a   Lev, Dina ^a   Setton, Arik ^a   Cope, Andrew P ^c   Wallach, David ^b   Klausner, Joseph ^a  

^a TEL AVIV UNIVERSITY   (Israel)

^b WEIZMANN INSTITUTE OF SCIENCE   (Israel)

^c STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

Author keywords

Cancer; Isolated limb perfusion; Septic shock; Soluble tumor necrosis factor receptors; Tumor necrosis factor

Indexed keywords

TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR RECEPTOR;

ADULT; AGED; ARTICLE; BLOOD VESSEL PERMEABILITY; CANCER PATIENT; CLINICAL ARTICLE; HEMODYNAMIC MONITORING; HUMAN; LIMB PERFUSION; PATHOPHYSIOLOGY; PRIORITY JOURNAL; SEPTIC SHOCK;

EID: 0032006611     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI694     Document Type: Article

References (51)

1. Grunfeld, C., and M.A. Palladino. 1990. Tumor necrosis factor: immunologic, antitumor, metabolic and cardiovascular activities. Adv. Intern. Med. 35: 45-72.
2. Shalaby, M., B. Aggarwal, E. Rinderknecht, L.P. Svedersky, B.S. Finkle, and M.A. Palladino. 1985. Activation of human polymorphonuclear neulrophil functions by interferon-gamma and tumor necrosis factors. J. Immnunol. 135: 2069-2073.
3. Gamble, J., J. Harlan, S.J, Klebanoff, and M.A. Vadas, 1985. Stimulation of the adherence of neutrophils to umbilical vein endothelium by human recombinant tumor necrosis factor. Proc. Nutl. Acad. Sci. USA. 82:8667-8771.
4. Philip, R., and L. Epstein. 1986. Tumor necrosis factor as immunomodulator and mediator of monocyte cytotoxicity induced by itself, gamma-interferon and interleukin-1. Nature. 323:86-89.
5. Yokota, S., T. D. Geppert, and P.E. Lipsky. 1988. Enhancement of antigen and mitogen induced human T lymphocyte proliferation by tumor necrosis factor.J Immunol 140:531-536.
6. Scheurich, P., B. Thoma, U. Ucer, and K. Pfizenmaier, 1987. Immunoregulatory activity of recombinant human tumor necrosis factor (TNF)-alpha: induction of TNF receptors on human T cells and TNF-alpha-mediatcd enhancement of T cell responses. J. Immunol. 138:1786-1790.
7. DeMeules, J.E., F.A. Pigula, M. Mueller, S.J. Raymond, and R.L. Gamelli. 1992. Tumor necrosis factor and cardiac function. J. Trauma. 32:686-692.
8. Parrillo, J.E., M.M. Parker, C. Natanson, A.F. Suffredini, R.L. Danner, R.E. Cunnion, and F.P. Oguibene. 1990. Septic shock in humans. Advances in the understanding of pathogenesis, cardiovascular dysfunction, and therapy. Ann. Int. Med. 113:227-242.
9. Vilcek, J., V.J. Palombella, D. Henriksen-DeStefano, C. Swenson, R. Feinman, M. Hirai, and M. Tsujimoto. 1986. Fibroblast growth enhancing activity of tumor necrosis factor and its relationship to other polypeptide growth factors. J. Exp. Med. 163:632-643.
10. Frater-Schröder, M., W. Risau, R. Hallmann, P. Gautschi, and P. Böhlen. 1987. Tumor necrosis factor type α, a potent inhibitor of endothelial cell growth in vitro is angiogenic in vivo. Proc. Natl. Acad. Sci. USA. 84:5277-5281.
11. Seckinger, P., S. Isaaz, and J.M. Dayer. 1989. Purification and biologic activity of a specific tumor necrosis factor α inhibitor. J. Biol. Chem. 264:11966-11973.
12. Engelmann, H., D. Aderka, M. Rubinstein, D. Rotman, and D. Wallach. 1989. A tumor necrosis factor-binding protein purified to homogeneity from human urine protects cells from tumor necrosis factor toxicity. J. Biol. Chem. 264:11974-11980.
13. Olsson, I., M. Lantz, E. Nilsson, C. Peetre, H. Thysell, and A. Grubb. 1989. Isolation and characterization of a tumor necrosis factor binding protein from urine. Eur. J. Haematol. 42:270-275.
14. Tartaglia, A.T., D. Pennica, and D.V. Goeddel. 1993. Ligand passing: the 75-kDa tumor necrosis factor (TNF) receptor recruits TNF for signaling by the 55-kDa TNF receptor. J. Biol. Chem. 268:18542-18548.
15. Bigda, J., I. Beletsky, C. Brakebusch, Y. Varfolomeev, H. Engelmann, J. Bigda, H. Holtmann, and D. Wallach. 1994. Dual role of the p75 tumor necrosis factor (TNF) receptor in TNF cytotoxicity. J. Exp. Med. 180:445-460.
16. Engelmann, H., D. Novick, and D. Wallach. 1990. Two tumor necrosis factor binding proteins purified from human urine. J. Biol. Chem. 265:1531-1536.
17. Tracey, K.J., B. Beutler, F.L. Lowry, J. Merryweather, S. Wolpe, I.W. Milsark, R.J. Hariri, T.J. Fahey, A. Zentella, J.D. Albert, et al. 1986. Shock and tissue injury induced by recombinant human cachectin. Science. 234:470-474.
18. Tracey, K.J., Y. Fong, D.J. Hesse, K.R. Manogue, A.T. Lee, G.C. Kuo, S.F. Lowry, and A. Cerami. 1987. Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia. Nature. 330:662-664.
19. Mohler, K.M., D.S. Torrance, C.A. Smith, R.G. Goodwin, K.E. Stremler, V.F. Fung, H. Madani, and M.B. Widmer. 1993. Soluble tumor necrosis factor (TNF) receptors are effective therapeutic agents in lethal endotoxemia and function simultaneously as both TNF carriers and TNF antagonists. J. Immunol. 151:1548-1561.
20. Ashkenazi, A., S.A. Marsters, D.J. Capon, S.M. Chamow, I.S. Figari, D. Pennica, D.V. Goeddel, M.A. Palladino, and D.H. Smith. 1991. Protection against endotoxic shock by a tumor necrosis factor immunoadhesin. Proc. Natl. Acad. Sci. USA. 88:10535-10539.
21. Lesslauer, W., H. Tahuchi, R. Gentz, M. Brockhaus, E.J. Schlaeger, G. Grau, P.F. Piguet, P. Pointaire, P. Vassalli, and H. Loetscher. 1991. Recombinant soluble tumor necrosis factor receptor proteins protect mice from lipopolysaccharide-induced lethality. Eur. J. Immunol. 21:2883-2886.
22. Fisher, C.J., Jr., J.M. Agosti, S.M. Opal, S.F. Lowry, R.A. Balk, J.C. Sadoff, E. Abraham, R.M. Schein, and E. Benjamin. 1996. Treatment of septic shock with tumor necrosis factor receptor:Fc fusion protein. The soluble TNF Receptor Sepsis Study Group. N. Engl. J. Med. 334:1697-1702.
23. Abraham, E., R. Wunderink, H. Silverman, T.M. Perl, S. Nasraway, H. Levy, R. Bone, R.P. Wenzel, R. Balk, R. Allred, et al. 1995. Efficacy and safety of a monoclonal antibody to human tumor necrosis factor alpha in patients with sepsis syndrome: a randomized, controlled, double blind, multicenter clinical trial. JAMA (J. Am. Med. Assoc.) 273:934-941.
24. Kaul, M., J. Eiselstein, J. Kempeni, and L. Daum. 1996. TNF neutralization in sepsis guided by IL-6 serum levels. Eur. Cytokine Netw. 7:283. (Abstr.)
25. Abraham, E., M.P. Glauser, T. Butler, J. Garbino, D. Gelmont, P.F. Laterre, K. Kudsk, H.A. Bruining, C. Otto, E. Tobin, et al. 1997. p55 Tumor necrosis factor receptor fusion protein in the treatment of patients with severe sepsis and septic shock. A randomized controlled multicenter trial. Ro 45-2081 study group. JAMA (J. Am. Med. Assoc.). 277:1531-1538.
26. Lienard, D., P. Ewalenko, J,J. Delmotte, N. Renard, and R.J. Lejeune. 1992. High-dose recombinant tumor necrosis factor alpha in combination with interferon gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma. J. Clin. Oncol. 10:52-60.
27. Eggermont, A.M.M., D. Lienard, H. Schraffordt-Koops, and F. Rosenkaimer, and F.J. Lejeune. 1993. Treatment of irresectable soft tissue sarcomas of the limb by isolation perfusion with high dose TNFα in combination with interferon-γ and melphalan. In W. Fiers and W.A Buurman, editors. Tumor Necrosis Factor: Molecular and Cellular Biology and Clinical Relevance. S. Karger AG, Basel. 239-243.
28. Eggimann, P., R. Chiolero, P.C. Chassot, D. Lienard, J. Gerain, and F. Lejeune. 1995. Systemic and hemodynamic effects of recombinant tumor necrosis factor alpha in isolation perfusion of the limbs. Chest. 107:1047-1082.
29. Yang, J.C., D.L. Fraker, A.K. Thom, H.I. Pass, and S.A. Rosenberg. 1995. Isolation perfusion with tumor necrosis factor-alpha, interferon gamma and hyperthermia in the treatment of localized and metastatic cancer. Recent Results Cancer Res. 138:161-166.
30. Lantz, M., S. Malik, M. Slevin, and I. Olsson. 1990. Infusion of tumor necrosis factor (TNF) causes an increase in circulating TNF-binding protein in humans. Cytokine. 2:402-406.
31. Sorkin, P., S. Abu-Abid, D. Lev, M. Gutman, D. Aderka, P. Halpern, A. Setton, N. Kudlic, J. Bar-On, V. Rudich, et al. 1995. Systemic leakage and side effects of tumor necrosis factor α administered via isolated limb perfusion can be manipulated by flow rate adjustment. Arch. Surg. 130:1079-1084.
32. Krementz, E.T., R.D. Cartger, C.N. Sutherland, and I. Hutton. 1977. Chemotherapy of sarcomas of the limbs in regional perfusion. Ann. Surg. 185: 555-564.
33. Aderka, D., H. Engelmann, V. Hornick, Y. Skornick, Y. Levo, D. Wallach, and G. Kushtai. 1991. Increased serum levels of soluble receptors for tumor necrosis factor in cancer patients. Cancer Res. 51:5602-5607.
34. Aderka, D. A.J. Wysenbeek, H. Engelmann, A.P. Cope, F. Brennan, Y. Molad, V. Hornik, Y. Levo, R.N. Maini, M. Feldmann, and D. Wallach. 1993. Correlation between serum levels of soluble tumor necrosis factor receptor and disease activity in systemic lupus erythematosus. Arthritis Rheum. 36:1111-1120.
35. Cope, A.P., D. Aderka, M. Doherty, H. Engelmann, D. Gibbons, A. Jones, M.F. Brennan, R.N. Maini, D. Wallach, and M. Feldmann. 1992. Increased levels of soluble tumor necrosis factor receptors in the sera and synovial fluid of patients with rheumatic diseases. Arthritis Rheum. 35:1160-1169.
36. Engelmann, H., H. Holtmann, C. Brakebusch, Y. Shemer-Avni, I. Sarov, Y. Nophar, E. Hadas, O. Leitner, and D. Wallach. 1990. Antibodies to a soluble form of a tumor necrosis factor (TNF) have TNF-like activity. J. Biol. Chem. 265:14497-14504.
37. Aderka, D., H. Engelmann, Y. Maor, C. Brakebusch, and D. Wallach. 1992. Stabilization of the bioactivity of tumor necrosis factor by its soluble receptors. J. Exp. Med. 175:323-329.
38. De Groote, D., G.E. Grau, I. Dehart, and P. Franchimont. 1993. Stabilisation of functional tumor necrosis factor-α by its soluble TNF receptors. Eur. Cytokine Netw. 4:359-362.
39. Beutler, B., I.W. Milsark, and A. Cerami. 1985. Cachectin/tumor necrosis factor: production, distribution and metabolic fate in vivo. J. Immunol. 135: 3972-3977.
40. Tilg, H., E. Trehu, M.B. Atkins, C.A. Dinarello, and J.W. Mier. 1994. Interleukin-6 (IL-6) as an anti-inflammatory cytokine: induction of circulating IL-1 receptor antagonist and soluble tumor necrosis factor receptor p55. Blood. 83:113-118.
41. Wallach, D. 1984. Preparations of lymphotoxin induce resistance to their own cytotoxic effect. J. Immunol. 132:2464-2469.
42. Girardin, E., P. Roux-Lombard, G.E. Grau, P. Suter, H. Gallati, and J.M. Dayer. 1994. Imbalance between TNFα and soluble TNF receptor concentrations in severe meningcicoccaemia. The J5 Study Group. Immunology. 76: 20-23.
43. Aderka, D., H. Engelmann, and D. Wallach. 1993. Soluble TNF receptors in health and disease. In Tumor Necrosis Factor: Molecular and Cellular Biology and Clinical Relevance. W. Fiers and W.A. Buurman, editors, S. Karger AG, Basel. 191-198.
44. Schroder, J., F. Stuber, H. Gallati, F.U. Schade, and B. Kremer. 1995. Pattern of soluble TNF receptors I and II in sepsis, Infection. 23:143-148.
45. Rothstein, J.L., and H. Schreiber. 1988. Synergy between tumor necrosis factor and bacterial products causes hemorrhagic necrosis and lethal shock in normal mice. Proc. Natl. Acad. Sci. USA. 85:607-611.
46. Natanson, C. W.D. Hoffman, A.F. Suffredini, P.Q. Eichacker, and R.L. Danner. 1994. Selected treatment strategies for septic shock on proposed mechanisms of pathogenesis. Ann. Int. Med. 120:771-783.
47. Natanson, C., R.L. Eichenholz, P.Q. Danner, G.C. Huffman, G.C. Kuo, S.M. Banks, T.J. Mac Vittie, and J.E. Parrillo. 1989. Endotoxin and TNF challenges in dog simulate the cardiovascular profile of human septic shock. J. Exp. Med. 169:823-832.
48. Suffredini, A.F., D. Reda, S.M. Banks, M. Tropea, J.M. Agosti, and R. Miller. 1995. Effects of recombinant dimeric TNF receptor on human inflammatory responses following intravenous endotoxin administration. J. Immunol. 155:5038-5045.
49. Killbourn, R.G., S.S. Gross, A. Juhran, J. Adams, O.W. Griffith, R. Levi, and R.F. Lodato. 1990. NG-methyl-L-arginine inhibits tumor necrosis factor-induced hypotension: implications for the involvemert of nitric oxide. Proc. Nutl. Acad. Sci. USA. 87:3629-3632.
50. Echtenacher, B., W. Falk, D.N. Mannel, and P.H. Krammer. 1990. Requirement of endogenous tumor necrosis factor/cachectin for recovery from experimental peritonitis. J. Immunol. 145:3762-3766.
51. Bagby, G.J., K.J. Plessala, L.A. Wilson. J.J. Thompson, and S. Nelson. 1991. Divergent efficacy of antibody to tumor necrosis factor-α in intravascular and peritonitis models of sepsis. J. Infect. Dis. 163:83-88.